BD drives the future of immunology research with expanded offerings

BD (Becton, Dickinson and Company) announced the commercial release of the BD AbSeq assay to analyze protein expression at the single-cell level using high-throughput sequencing. The assay brings together high-quality antibodies from the BD Pharmingen portfolio with oligonucleotides, allowing researchers to perform single-cell protein analysis on the BD rhapsody single-cell analysis system. When used together, these research tools enable researchers to simultaneously analyze RNA and proteins in thousands of individual cells and develop a more complete picture of the role genes and proteins play in biological systems. The product leverages 40 years of BD leadership in immunology research. Initially available with more than 100 different human antibody–oligonucleotide combinations, over time, BD will rapidly expand the portfolio to utilize its vast library of flow cytometry-proven human and mouse antibody clones, helping researchers to advance the understanding of complex diseases. Customers can also design their own custom conjugates.